Valiant Laboratories Ltd. Hits Upper Circuit for the 2nd Straight Session on BSE, 16 October 2026

On 16 October 2026, Valiant Laboratories Ltd. (VALIANTLAB) hit the upper circuit on BSE at Rs 134.6, a 4.99% positive move from the previous close of Rs 128.2. The company’s market cap stood at Rs 696.29 crore. The upper circuit price for the session was Rs 134.6.

The Valiant Laboratories upper circuit streak has now run for 2 straight sessions. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Key Takeaways

• Valiant Laboratories Ltd. (VALIANTLAB) hit the upper circuit on BSE at Rs 134.6 on 16 October 2026.
• The session move was +4.99% against a previous close of Rs 128.2.
• Market capitalisation stood at Rs 696.29 crore with a PE ratio of 43.5.
• This is the 2nd straight session at the upper circuit, with the run starting on 15 October 2026.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

All figures above are as of 16 October 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Valiant Laboratories Ltd. opened at Rs 129.1 on BSE, compared with a previous close of Rs 128.2. During the session, the stock traded between Rs 127.4 and Rs 134.6 before touching the upper circuit price of Rs 134.6.

The absolute day change was Rs 6.4, while the percentage move was 4.99%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 134.6, which is the level the price reached.

The Valiant Laboratories Upper Circuit Streak So Far

This is session 2 of an unbroken run for Valiant Laboratories Ltd. The streak began on 15 October 2026, from a base price of Rs 122.2. Across the run the stock has moved 10.15% in total.

A repeated upper circuit matters more than a single one. It says the order book has stayed one-sided across multiple sessions rather than reacting to a single day of news, and for anyone holding the stock it means the price on screen has been hard to trade at for several days running.

This page is the running record for the streak and is updated each session rather than being replaced by a fresh article. That keeps one address for the event instead of splitting the same story across competing pages.

Why Valiant Laboratories Ltd. Hit Upper Circuit

Valiant Laboratories Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the upper circuit level of Rs 134.6.

What the Valiant Laboratories Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Valiant Laboratories Ltd., the captured upper circuit price was Rs 134.6 on 16 October 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Valiant Laboratories Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Valiant Laboratories Ltd., PE ratio was 43.5, PB ratio was 2.1, book value was Rs 61.13, EPS was 2.95, ROCE was -0.4%, dividend yield was 0% and debt-to-assets ratio was 0.52, on a market cap of Rs 696.29 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

The reported EPS and return on equity for Valiant Laboratories Ltd. point in opposite directions in the source dataset, which cannot both be right. No conclusion about profitability is drawn here until that is resolved.

At the reported PB ratio of 2.1, the market valued Valiant Laboratories Ltd. above its reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Valiant Laboratories Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Several of these peers are far larger by market capitalisation than Valiant Laboratories Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Valiant Laboratories Ltd.’s PE ratio was 43.5, compared with an available peer PE average of 73.69, calculated from the 3 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical Snapshot

The technical snapshot adds context: RSI was 92.93, the 50-day moving average was 121.9 and the 200-day moving average was 84.67.

What Readers Should Know

The main confirmed fact is that Valiant Laboratories Ltd. hit the upper circuit on BSE at Rs 134.6 on 16 October 2026, with a 4.99% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Valiant Laboratories Ltd. hit upper circuit on 16 October 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

How many sessions has Valiant Laboratories Ltd. hit upper circuit in a row?

This is session 2 of the current run, which began on 15 October 2026. This page is updated each session rather than replaced with a new article.

What was VALIANTLAB share price on 16 October 2026?

The last traded price used in this article was Rs 134.6 on BSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for VALIANTLAB?

The upper circuit price was Rs 134.6. The stated exchange upper circuit limit was Rs 134.6. The event numbers in this article are aligned to BSE.

What is Valiant Laboratories Ltd.’s market cap and PE ratio?

Valiant Laboratories Ltd.’s market cap was Rs 696.29 crore. PE ratio was 43.5.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 16 October 2026.

Does hitting an upper circuit mean Valiant Laboratories Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Valiant Laboratories Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Valiant Laboratories Ltd. the stated limit was Rs 134.6. For this session, Valiant Laboratories Ltd. moved 4.99%.